POMBILITI subst sèche 105 mg flac
7680678040015
CH-67804
A16AB23
07.14.0.
Reimbursement limitations:
POMBILITI
Évaluation pour commencer la thérapie avec Pombiliti et Opfolda:
Le traitement par Pombiliti et Opfolda …
1 / 3
google
Details
- Product number
- 6780401
- CPT
- -
- Packaging group
- 1
- Unit
- Ampulle(n)
- Composition
- cipaglucosidasum alfa 105 mg, natrii citras dihydricus corresp. natrium 10.5 mg, acidum citricum monohydricum, mannitolum, polysorbatum 80, pro vitro.
Articles (1)
Pombiliti 105 mg, Pulver für ein Konzentrat zur Herstellung einer Infusionslösung
Pulver für ein Konzentrat zur Herstellung einer Infusionslösung
1
Official Swissmedic V2 data
Additional information from the official database
Official medical documents
Detailed composition
| Substance | Quantity | Type | Category |
|---|---|---|---|
|
(N/A)
|
105.0 MG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
10.5 MG | Substance | HBESI |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
Reimbursement information
Public price
CHF 1112.25
Specialties list
Yes
Generic
No
Reimbursement limitation
SL addition date:
01/01/2025
Authorization holder
Amicus Therapeutics Switzerland GmbH
8008 Zürich
Authorization information
- Swissmedic authorization number
- 67804
- Drug name
- Pombiliti, Pulver für ein Konzentrat zur Herstellung einer Infusionslösung
- Galenic form
- PULPI
- ATC Code
- A16AB23
- Authorization status
- Z
- Dispensation category
- A
- First authorization
- 04/07/2024
- Authorization expiration date
- 03/07/2029
- IT number
- 07.14.0.
- Domain
- Human medicine
Packaging details
- Description (FR)
- POMBILITI subst sèche 105 mg flac
- Description (DE)
- POMBILITI Trockensub 105 mg Durchstf
- Market launch
- 04/07/2024
- Narcotic (BTM)
- No